Increasing the dose to compensate for poor absorption is an inefficient and unreliable research method
it's how 503A compounding pharmacy law works
Youre skipping doses
Approximately 20%-30% of individuals with MASLD progress to MASH, characterized by hepatocyte ballooning, lobular inflammation, and variable fibrosis, and 10%-20% of MASH patients develop advanced fibrosis (stages F3-F4) or cirrhosis over their lifetime [6,13]
Ricca, V., Mannucci, E., Moretti, S., Di Bernardo, M., Zucchi, T., Cabras, P
When you think about antioxidants, carnosine may not be the first supplement to come to mind